pharmaphorum

OCTOBER 17, 2023

Roche builds gene therapy portfolio with SpliceBio deal Phil.Taylor Tue, 17/10/2023 - 11:18 Bookmark this

100

100

Fierce Pharma

NOVEMBER 15, 2022

Indivior inks $145M Opiant buyout to add nasal opioid overdose drug to portfolio. Tue, 11/15/2022 - 09:15.

130

130

PharmaTech

FEBRUARY 15, 2024

BioVaxys has acquired the full portfolio of discovery, preclinical, and clinical development-stage assets of the former IMV.

52

52

MedCity News

JANUARY 8, 2023

Zimmer Biomet pursued the deal to grow its sports medicine portfolio and gain entry into the high-growth rotator cuff augmentation submarket, an executive said. Orthopedics giant Zimmer Biomet entered into a definitive agreement to acquire Embody, a company that makes collagen-based implants designed to heal soft tissue injuries.

Medicine 111

Medicine 111

Clarivate

JULY 19, 2023

To turn a patent portfolio into a strategic asset, you need to see both the forest and the trees. Within this blog, we explore the process and value of optimizing your patent strategy through a three-phase patent portfolio analysis. The portfolio audit phase gives you a snapshot of the historical portfolio.

Competition 52

Competition Management Marketing 52

Pharmaceutical Technology

OCTOBER 12, 2023

Astria Therapeutics has signed a global exclusive agreement to license Ichnos Sciences’ OX40 portfolio for treating atopic dermatitis (AD).

52

52

pharmaphorum

JANUARY 9, 2023

per ADS, representing an approximate additional $225 million of potential consideration, based on certain milestones being achieved with Amryt’s Filsuvez, that will see the Italian company expand its rare disease medicine portfolio. The post Chiesi expands rare disease portfolio with Amryt Pharma acquisition appeared first on.

Pharma 80

Pharma Biopharma Medicine Management 80

PharmaTech

FEBRUARY 21, 2024

GSK is expanding its respiratory biologics portfolio with its acquisition of Aiolos Bio and its novel therapy, AIO-001.

52

52

Pharmaceutical Technology

NOVEMBER 21, 2023

Merck & Co will acquire all outstanding shares of Caraway, which has a preclinical-stage drug portfolio, through a subsidiary.

52

52

Pharmaceutical Technology

SEPTEMBER 15, 2023

Generate:Biomedicines has secured $273m in Series C financing round to expedite its generative AI therapeutics portfolio.

52

52

Fierce Pharma

MARCH 12, 2024

The antibody-drug conjugate (ADC) Adcetris has given Pfizer’s oncology department its first pivotal trial win from the legacy Seagen portfolio since the $43 billion merger. | The antibody-drug conjugate Adcetris has given Pfizer’s oncology department its first pivotal trial win from the legacy Seagen portfolio since the $43 billion merger.

237

237

European Pharmaceutical Review

JANUARY 18, 2023

Pfizer has announced it is expanding its ‘An Accord for a Healthier World’ initiative, to include its full portfolio of medicines and vaccines for which Pfizer has global rights. Access to Pfizer’s expanded medicine portfolio. billion people in 45 lower-income countries (LICs). million deaths that occur each year. “We

Medicine 82

Medicine Government Pharma Leads 82

PharmaTech

JUNE 1, 2023

Through the acquisition, Avacta gains Coris’ product portfolio consisting of diagnostic tests for respiratory, gastroenteric, and blood-borne pathogens as well as for the detection of antibiotic resistance markers.

59

59

Pharma Leaders

JUNE 8, 2023

Samsung Biologics has announced a strategic collaboration with Pfizer for the long-term commercial manufacturing of the latter’s multi-product biosimilars portfolio. As per the new agreement terms , Samsung Biologics will provide Pfizer with more capacity for manufacturing for the biosimilars portfolio.

Manufacturing 52

Manufacturing Medicine Patients Pharmaceutical 52

PharmExec

DECEMBER 4, 2023

which has an R&D portfolio that includes clinical stage subcutaneous and oral incretins for the treatment of patients with obesity, both with and without diabetes. Roche announces definitive merger agreement to acquire Carmot Therapeutics, Inc.,

Patients 52

Patients 52

European Pharmaceutical Review

JUNE 13, 2023

The acquisition will significantly expand Novartis’ renal portfolio. acquisition to boost Novartis’ renal portfolio appeared first on European Pharmaceutical Review. Novartis has entered into an acquisition agreement with biopharma Chinook Therapeutics for a value up to £2.5 The post £2.5b

Biopharma 52

Biopharma Safety Leads Pharmaceutical 52

Pharmaceutical Technology

FEBRUARY 28, 2023

Dr Reddy’s Laboratories has signed a definitive agreement to buy Australian company Mayne Pharma Group’s US generic prescription product portfolio in a deal valued at approximately $105m. Under the deal, the company will buy the portfolio for around $90m in an upfront cash payment.

Pharma 52

Pharma Prescription Retail Competition 52

Pharmaceutical Technology

SEPTEMBER 5, 2023

Cipla Medpro South Africa has signed a binding term sheet to acquire Actor Pharma to bolster over-the-counter (OTC) product portfolio.

Pharma 52

Pharma 52

PharmExec

APRIL 5, 2023

Looking at corporate value through a portfolio lens provides an astute and reliable path to genuine value creation.

52

52

pharmaphorum

NOVEMBER 25, 2022

The pain products complement the German drugmaker’s current portfolio which includes a topical capsaicin product called Qutenza for post-shingles nerve pain and diabetic nerve pain affecting the feet, along with non-opioid analgesic resiniferatoxin which recently advanced into phase 3 testing in patients with osteoarthritis.

Medicine 52

Medicine Marketing Pharma Management 52

PharmExec

APRIL 9, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

52

52

Clarivate

JULY 31, 2023

Following the acquisition of Dialog Solutions as part of the ProQuest M&A in December 2021, Dialog Solutions products and services will be folded into the Clarivate portfolio of offerings for Life Sciences & Healthcare. Today, the Dialog Solutions brand has been integrated into Clarivate.

Healthcare 52

Healthcare Healthcare Safety Competition 52

Pharmaceutical Technology

JUNE 14, 2023

Blue Water Biotech has expanded its commercial portfolio with the purchase agreement of six assets from WraSer. The six newly acquired medicines join Entadfi (finasteride and tadalafil) in Blue Water’s portfolio. The agreement includes an $8.5m cash payment and the offering of one million restricted shares.

Food and Drug Administration 52

Food and Drug Administration FDA Distribution Food 52

PharmaTech

APRIL 12, 2023

The BalanCD CHO media portfolio is designed to ensure maximized growth, viability, and productivity of CHO cell lines.

Media 52

Media 52

Pharmaceutical Technology

JANUARY 23, 2023

Disc Medicine CEO and president John Quisel said: “Disc has built deep expertise in the role of iron homeostasis in hematologic disorders, and I am thrilled to expand our portfolio with these highly complementary antibody programmes. “We

Food and Drug Administration 52

Food and Drug Administration Medicine Food FDA 52

Pharmaceutical Technology

MAY 30, 2023

EffRx has received several European regulatory approvals for drugs in its portfolio. The company has developed three bisphosphonates, clodronate, alendronate and Nerixia (neridronate), for the treatment of bone pathologies such as osteoarthritis. Bisphosphonates are drugs that slow the progression of bone loss.

Pharmaceutical Distribution 52

Pharmaceutical Distribution Distribution Medicine Pharmaceutical 52

Pharmaceutical Technology

JUNE 16, 2023

from Flanders Innovation & Entrepreneurship (VLAIO) to further advance its oncology portfolio targeting RNA. Flamingo Therapeutics has received a research grant of €1.7m

Leads 69

Leads Pharmaceutical Patients 69

MedCity News

OCTOBER 17, 2023

Thermo Fisher Scientific is acquiring Olink, a company that provides proteomics analysis tools and services used in drug discovery research. Olink’s growing revenue will help shore up a Thermo Fisher business segment whose sales have fallen due to declining Covid-19 testing demand.

Sales 117

Sales Biopharma Pharma 117

Dinamic OR

JANUARY 14, 2022

So, what are the key qualities of a winning medical device product portfolio? Given the fact that these are the top qualities sought by healthcare personnel when purchasing medical devices, it behooves the medical device salesperson to build a portfolio that includes products satisfying these wants and needs. Combining it all .

Medical 52

Medical Healthcare Healthcare Patients 52

Fierce Pharma

APRIL 15, 2024

As Genentech bolsters its hematology portfolio with new antibody drugs and bispecifics, the Roche unit has revealed a trial win that could push its recently approved T-cell engager Columvi int | The study paired Columvi, a CD20xCD3 bispecific T-cell engager, with the chemotherapy GemOx (glofitamab-gxbm) in patients who’d tried at least one prior line (..)

Patients 170

Patients 170

Legacy MEDSearch

FEBRUARY 14, 2023

Tioga Cardiovascular, a Shifamed portfolio company that aims to redefine structural heart valve replacement, announced today the first closing of its $30M Series C financing. The post TIOGA CARDIOVASCULAR, A SHIFAMED PORTFOLIO COMPANY, CLOSES $30M IN SERIES C FINANCING appeared first on Legacy MedSearch | Medical Device Recruiters.

Recruitment 52

Recruitment Management Medical Specialization 52

Fierce Pharma

SEPTEMBER 7, 2023

Analysts anticipate that the trend will continue in 2023 and into 2024 as companies attempt to beef up their portfolios. . | Biopharma M&A is on an uptick compared to the post-pandemic doldrums of the last two years.

Biopharma 328

Biopharma Pharma 328

PharmaTimes

JULY 12, 2023

Company adds a number of additional brands from Sanofi following initial take overs in 2021 - News - PharmaTimes

92

92

Pharmaceutical Technology

JULY 8, 2022

AstraZeneca is looking to diversify its haematology portfolio to maintain a leadership position in the haematology space following the success of its blockbuster Bruton tyrosine kinase inhibitor Calquence (acalabrutinib), used widely in chronic lymphocytic leukaemia.

Safety 59

Safety Sales Marketing Patients 59

PharmaTech

APRIL 14, 2023

The acquisition of Cell Systems will bolster AnaBios’ portfolio of human tissue and cells for use in drug discovery.

59

59

Fierce Pharma

DECEMBER 10, 2023

Roche’s blood cancer portfolio is booming with new life thanks to the antibody-drug conjugate Polivy and bispecifics. |

195

195

Fierce Pharma

OCTOBER 3, 2023

As Galderma attempts to round out its injectable aesthetics portfolio with approvals to resolve crow’s feet and frown lines, the FDA spotted a few manufacturing wrinkles in its RelabotulinumtoxinA | The agency spotted issues relating to chemistry, manufacturing and controls (CMC) processes in the company's application for its liquid botulinum (..)

Manufacturing 282

Manufacturing FDA 282